By Daniel Webster, dWeb.News Publisher
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mediar Therapeutics today announced Simon Sturge has joined the firm as executive chairman. Sturge has extensive experience in large pharmaceutical operations as well as biopharma startups. Mediar Therapeutics today announced that Simon Sturge has been appointed executive chairman. This is because Mediar is developing a platform technology focused on myofibroblast, which is an important driver in fibrosis pathology.
“We are thrilled to welcome Simon to Mediar as we move towards bringing our breakthrough treatments for fibrosis to the clinic,” said Meredith Fisher, Ph.D., founding CEO of Mediar and a partner at Mass General Brigham Ventures. “Simon has a track record of driving drug development and leading major pharmaceutical organizations making him an ideal team member to guide Mediar through its next phase of development.”
Most recently Sturge was CEO of Kymab which is a company that develops innovative anti-inflammatory treatments. Sturge was the one who negotiated the sale of Kymab to Sanofi S.A. in April for $1. 45 Billion. Before joining Kymab Sturge was chief operating officer at Merck Healthcare. He was responsible for global manufacturing and commercial operations as well as being a member the Merck Healthcare executive board.
Before joining Kymab, Sturge was the senior vice president of biologics at Boehringer Ingelheim, where he managed the global biosimilars business for German biopharma. He was also chairman of two biopharma startup companies, Silence Therapeutics & Nemesis Biosciences.
Sturge said, “I’m excited about helping Mediar into the next stage of its development.” “I believe my background developing and advancing novel antibody-based therapeutics at Kymab will be especially helpful as Mediar builds a pipeline of antibody-based treatments for fibrosis.”
Sturge added, “Mediar’s plan to target fibrotic mediators to halt, and even reverse, fibrosis has the potential to transform the way we treat this disease, which manifests in many different forms throughout the body.”
Earlier this year, Mediar announced that Pfizer Ventures and Ono Venture Investment had invested in the firm, bringing the total seed round to $20 million.
About Mediar Therapeutics
Mediar Therapeutics is a discovery stage biotechnology company developing treatments to halt, or even reverse, fibrosis. Our platform and pipeline is based on a new class of targets, fibrotic mediators. These mediators play important roles in modulating myofibroblasts. These cells can cause organ damage and disease, such as liver cirrhosis. Mediar was founded by prominent fibrosis researchers at Massachusetts General Hospital and Brigham and Women’s Hospital . For more information, contact firstname.lastname@example.org.
More dWeb.News Business News at https://dweb.news/news-sections/business-news/